Clinical trial · Interventional
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors
NCT00454649CI-TRIAL-00006662completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Axitinib + Capecitabine (Cohort 6) | Drug | — | UNRESOLVED |
| Axitinib + Capecitabine (Cohort 7) | Drug | — | UNRESOLVED |
| Axitinib + Docetaxel + Carboplatin (Cohort 4a) | Drug | — | UNRESOLVED |
| Axitinib + Docetaxel (Cohort 5) | Drug | — | UNRESOLVED |
| Axitinib + Gemcitabine + Cisplatin (Cohort 8) | Drug | — | UNRESOLVED |
| Axitinib + Paclitaxel + Carboplatin (Cohort 1) | Drug | — | UNRESOLVED |
| Axitinib + Paclitaxel + Carboplatin (Cohort 2) | Drug | — | UNRESOLVED |
| Axitinib + Paclitaxel + Carboplatin (Cohort 3) | Drug |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Axitinib [AG-013736] + chemotherapy combination
- description
- The following separate groups were included: axitinib 1. plus carboplatin/paclitaxel in three different schedules 2. plus paclitaxel 3. plus docetaxel/carboplatin 4. plus docetaxel 5. plus capecitabine 6. plus gemcitabine/cisplatin 7. plus pemetrexed/cisplatin
- interventionNames
- Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 1)
- Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 2)
- Drug: Axitinib + Paclitaxel + Carboplatin (Cohort 3)
- Drug: Axitinib + Paclitaxel (Cohort 4)
- Drug: Axitinib + Docetaxel + Carboplatin (Cohort 4a)
- Drug: Axitinib + Docetaxel (Cohort 5)
- Drug: Axitinib + Capecitabine (Cohort 6)
- Drug: Axitinib + Capecitabine (Cohort 7)
- Drug: Axitinib + Gemcitabine + Cisplatin (Cohort 8)
- Drug: Axitinib + Pemetrexed + Cisplatin (Cohort 9)
Primary outcomes (1)
- measure
- Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced solid tumors suitable for treatment with Taxanes, with or without carboplatin, or treatment with Capecitabine, Gemcitabine/Cisplatin. or Pemetrexed/Cisplatin Exclusion Criteria: * Tumors abutting or providing support for blood vessels * Any significant gastrointestinal abnormalities or active bleeding.
References
Publications (0)
Data not yet available
No reference posted for this study.